Projects › Road to the Cure

GISTT RACE · Research Alliance for CurE

Road to the Cure

Four laboratories on two continents, one question: which GIST cells survive the best drugs we have, and how do we remove them?

LeadsS. Bauer, P. Chi, R. DeMatteo, J. Fletcher
TypeTranslational research program, four laboratories
Funded byRoad to the Cure Foundation
StatusRunning

Central question 11: Why do some tumor cells survive treatment without being resistant, and how do we eliminate them?

The problem

First-line KIT/PDGFRA-inhibitors, imatinib and avapritinib, shrink most advanced GISTs, yet some tumor cells always survive (persist) and eventually cause resistance. Strikingly, the best response of most GIST metastases with acquired imatinib resistance is persistence rather than regression. Therefore, cures for both treatment-naïve and treatment-resistant GISTs require strategies that remove these persister cells.

Hypothesis

KIT and PDGFRA oncogenic mutations induce GIST proliferation and survival in part through the PI3K/AKT and MEK/MAPK signaling pathways. Preliminary studies in clinical specimens show that GIST cells persisting during effective KIT/PDGFRA-inhibitor therapies depend on combinations of:

  1. persistent KIT activation
  2. activation of other tyrosine kinases which (like KIT and PDGFRA) activate the PI3K/AKT and MEK/MAPK signaling pathways and
  3. reactivation of MEK/MAPK by KIT/PDGFRA-independent feedback loops

We hypothesize that insufficient blockade of the PI3K/AKT and MEK/MAPK pathways is a major roadblock to cures for metastatic GIST.

Aims

  1. MechanismsFind the mechanisms of persistence during effective therapy.
  2. ModelsBuild models of persistence and test treatments that block it.
  3. TrialsDesign clinical trials aimed at longer survival and cure.
  4. SharingAll four labs share samples, data and reagents.

The four laboratories

Bauer lab

West German Cancer Center, University Hospital Essen · Essen, Germany

Large biobank and long clinical follow-up of patients treated over two decades, plus isogenic GIST cell lines covering many KIT and PDGFRA variants. Studies whether stronger KIT inhibition deepens cell kill, and how mutations downstream of KIT and their zygosity shape persistence. Leads the shared sample inventory, the joint omics database and a registry of response at surgery.

Chi lab

Memorial Sloan Kettering Cancer Center · New York, USA

Tumor-intrinsic and microenvironment mechanisms of adaptive resistance. Builds on the discovery of ETV1 and FOXF1 as lineage survival factors: screens for druggable regulators of FOXF1, single-cell and spatial profiling of responders and non-responders, and neoadjuvant combination trials with imatinib.

DeMatteo lab

Perelman School of Medicine, University of Pennsylvania · Philadelphia, USA

Fresh tissue from surgery in untreated, responding and resistant GIST, with bulk and single-cell RNA sequencing. Develops immunotherapy to combine with kinase inhibitors, including preoperative trials, uses engineered mouse models of GIST, and explores steroid hormone receptors as non-kinase targets.

Fletcher lab

Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School · Boston, USA

A repository of persistent metastases removed after long-term or neoadjuvant kinase-inhibitor therapy, compared with untreated and progressing tumors. Asks whether persistence mechanisms are the same across all lesions in a patient, and uses genome-wide functional screens, transcriptomics and phospho-proteomics to find new targets.

For GISTT-RACE

The program answers central questions 3, 4 and 11 and supplies the targets for the combinations that the platform trial will test. Its biobanks and isogenic cell lines are part of the model platform.

Road to the Cure Collaborations

  1. please collaborate to maximize analyses of persistent GIST surgical specimens, particularly in patients receiving KIT/PDGFRA-inhibitors (typically imatinib) right up until the surgery. In the ideal circumstance, 1 or more progressing metastases and 1 or more stable/persisting metastases are snap-frozen from the same surgery.
  2. more experimental details/priorities for this RTTC section of GISTT-RACE will be provided in the coming months: please check back to see how you might fit in. Please also join for detailed discussions of persistence-targeting strategies at GISTT Summit 2027, SARCOMA P31 (GIST breakout), and SASS 2027.

To collaborate with the program, please contact info@gistt-race.org.